Premium
Pediatric toxic epidermal necrolysis treated successfully with infliximab
Author(s) -
Chafranska Lana,
Saunte Ditte M.,
Behrendt Nille,
Nygaard Ulrikka,
Christensen Ryan J.,
Sand Carsten,
Jemec Gregor B.
Publication year - 2019
Publication title -
pediatric dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.542
H-Index - 73
eISSN - 1525-1470
pISSN - 0736-8046
DOI - 10.1111/pde.13778
Subject(s) - toxic epidermal necrolysis , medicine , dermatology , infliximab , mycoplasma pneumoniae , hyperpigmentation , surgery , tumor necrosis factor alpha , pneumonia
Successful management of toxic epidermal necrolysis ( TEN ) with tumor necrosis factor‐α inhibitors has been described in adults. We present a case of a 7‐year‐old boy with infection‐associated TEN , diagnosed by typical clinical and histopathological features, most likely caused by Mycoplasma pneumoniae . Treatment with a single dose of infliximab 5 mg/kg intravenously on day 5 after the onset of symptoms was followed by cessation of all blister formation over 3 days and complete resolution within a week. Sequelae were mild, consisting of postinflammatory hyperpigmentation and dry eyes.